| HOME >> BIOLOGY >> TECHNOLOGY |
Biotechnology firm Divergence, Inc., a world leader in developing products for the control of parasites in agriculture and medicine, today announced that it has raised $11.8 million in a Series C financing round that will further its efforts to create solutions for one of the major causes of crop yield loss for farmers.
St. Louis, MO (PREWB) February 11, 2009 -- Biotechnology firm Divergence, Inc., a world leader in developing products for the control of parasites in agriculture and medicine, today announced that it has raised $11.8 million in a Series C financing round that will further its efforts to create solutions for one of the major causes of crop yield loss for farmers.
MidPoint Food and Ag Fund LP acted as lead investor in the round. Other institutional investors included Prolog Ventures LP and certain partners of William Blair & Co. The round included 41 returning investors including all members of Divergence's Board of Directors. The financing more than doubles the amount of equity capital raised by the company since its inception.
Proceeds from the financing will be used to advance Divergence's nematicide program. The company is developing molecules for the control of plant parasitic nematodes. Nematode control is the largest unsolved pest problem in agriculture limiting the yield of crops worldwide and causing billions of dollars in crop damage annually. Divergence has discovered the first novel mode of action for this market in more than 20 years. The new molecules feature human and environment safety profiles that are vastly superior to traditional nematicides. The funding will also support the Company's continued development of crops that are resistant to nematodes, as well as its innovative, broad-based research platforms Harvest™, STEM™ and RNA interference.
"This financing, especially given the sophistication of the participat
'/>"/>
| Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved |